NASDAQ$ORGO

Organogenesis Holdings Inc · Q4 2016 earnings

Q4 2016 earnings · · Investor relations

Headline financials

Total Revenue

$61.1K

No prior period
EPS (adj)

-$0.02

No prior period
Net Income

-$178K

No prior period
Operating Income

$178K

No prior period
Gross Profit

-$117K

No prior period
R&D Expense

$0.00

No prior period

Revenue & EPS history

Organogenesis · Revenue · Quarterly

$61.1K

Q4 2016
Beat estimate in 3 of 7 quarters(43%)
ActualEstimate

Revenue by segment

Organogenesis · $109M total across 2 segments · Q3 2023

  • Advanced Wound Care
    $101M-7.4%
  • Surgical & Sports Medicine
    $7.2M-1.4%

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2016

Historical avgQ4 2016

+2.8%

Avg return

Earnings day

+3.2%

Avg return

5 days after

+0.5%

Avg return

30 days after

47%

17 / 36 earnings

Positive

+102.3%

Q4 2024

Best reaction

-42.4%

Q1 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-2.0%-6.2%-5.9%
Q4 2025-13.8%-22.4%-38.1%
Q3 2025+44.1%+66.6%+21.9%
Q1 2025-42.4%-43.6%-43.3%
Q4 2024+102.3%+95.8%+46.6%
Q3 2024+26.6%+10.3%+0.9%
Q2 2024+2.0%+6.4%-1.2%
Q1 2024+31.2%+23.2%+19.0%
Q4 2023-16.3%-20.3%-18.6%
Q3 2023+6.8%+22.9%+62.4%
Q2 2023-25.7%-27.0%-31.6%
Q1 2023+29.7%+43.2%+81.1%
Q4 2022+11.0%-2.9%-13.1%
Q3 2022-18.3%-11.5%-17.7%
Q2 2022-25.2%-26.6%-44.0%
Q1 2022+4.6%+9.8%-9.3%
Q4 2021+18.1%+15.6%+2.4%
Q3 2021-6.4%-5.0%-16.1%
Q2 2021+1.9%+2.5%+8.2%
Q1 2021-15.3%-11.3%-28.7%
Q4 2020+3.8%+8.5%+31.4%
Q3 2020+8.2%+5.2%+20.2%
Q2 2020+0.7%+1.5%+3.2%
Q1 2020-9.9%-18.8%+4.2%
Q4 2019-16.2%+11.6%+23.5%
Q3 2019+10.3%+8.8%-36.1%
Q2 2019-4.7%-10.8%+26.5%
Q1 2019-0.4%+1.0%+0.7%
Q4 2018-3.0%-5.3%-16.8%
Q4 2017-3.0%-5.3%-16.8%
Q2 2018+0.3%+0.2%+0.1%
Q1 2018+0.0%+0.4%+0.3%
Q3 2017+0.1%+0.1%-1.0%
Q2 2017+0.0%+0.1%+1.5%
Q1 2017-0.3%-0.3%+0.5%
Q4 2016+0.0%+0.0%+0.0%
Q3 2016
Q2 2016
Q1 2016

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro